Phase I/II Study of Stereotactic Ablative Radiotherapy Including Regional Lymph Node Irradiation in Patients with High-Risk Prostate Cancer (SATURN): Early Toxicity and Quality of Life

Two-year toxicity and quality of life (QOL) results are reported from a dose-escalated prostate SABR study for high-risk prostate cancer. Prostate, seminal vesicles, and pelvic lymph nodes were treated using a dose-painting schema up to 40Gy and 25Gy in 5 fractions, respectively, delivered weekly, in combination with androgen deprivation therapy. No grade 3 or higher CTCAE v 3.0 toxicity was noted. EPIC quality of life in all 4 domains was comparable to baseline at 24 months.

International journal of radiation oncology, biology, physics. 2018 Jul 30 [Epub ahead of print]

H B Musunuru, L D'Alimonte, M Davidson, L Ho, P Cheung, D Vesprini, S Liu, W Chu, H Chung, A Ravi, A Deabreu, L Zhang, K Commisso, D A Loblaw

Depatment of Human Oncology, University of Wisconsin, Madison., Odette Cancer Centre, Sunnybrook Health Sciences Centre; Department of Radiation Oncology, University of Toronto., Odette Cancer Centre, Sunnybrook Health Sciences Centre., Odette Cancer Centre, Sunnybrook Health Sciences Centre; Department of Radiation Oncology, University of Toronto; Department of Health Policy, Measurement and Evaluation, University of Toronto. Electronic address: .